ReviewOncology letters2026
Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma-like carcinoma (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer, the clinicopathological features and molecular mechanisms of which are markedly different from those of other lung cancer subtypes. In recent years, with in-depth research in molecular pathology and immunology, notable progress has been achieved in the pathogenesis, diagnostic methods and therapeutic strategies of PPLELC. Epidemiological studies have shown that PPLELC is closely associated with Epstein-Barr virus (EBV) infection and the role of EBV in tumorigenesis has become a particular research focus. In addition, the unique immune microenvironment characteristics of PPLELC provide potential targets for immunotherapy. The present review systematically summarizes the epidemiology, pathological features, molecular biological mechanisms and diagnostic methods of PPLELC and focuses on discussing the association between EBV infection and tumorigenesis, the characteristics of immune microenvironment, as well as the latest advances in targeted therapy and immunotherapy. The aim was to provide a comprehensive diagnostic and therapeutic framework for clinicians and to prospect future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.